Barinthus Biotherapeutics (STU:2AB) Gross Profit: €0.00 Mil (TTM As of Mar. 2026)

Barinthus Biotherapeutics  (STU:2AB) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Barinthus Biotherapeutics had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage

Barinthus Biotherapeutics Gross Profit Related Terms

The historical data trend for Barinthus Biotherapeutics's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Barinthus Biotherapeutics Gross Profit Chart

Barinthus Biotherapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Gross Profit	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

STU:2AB vs VTGN, PSTV, PVCT: Gross Profit Comparison

For the Biotechnology subindustry, Barinthus Biotherapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Barinthus Biotherapeutics Gross Profit vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's Gross Profit distribution charts can be found below:

* The bar in red indicates where Barinthus Biotherapeutics's Gross Profit falls into.

Barinthus Biotherapeutics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Barinthus Biotherapeutics's Gross Profit for the fiscal year that ended in Dec. 2025 is calculated as

Barinthus Biotherapeutics's Gross Profit for the quarter that ended in Mar. 2026 is calculated as

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Barinthus Biotherapeutics's Gross Margin % for the quarter that ended in Mar. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Barinthus Biotherapeutics Business Description